Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

  • Jr W
  • JE G
  • RF G
 et al. 
  • 3

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

PURPOSE There is no effective therapy for patients with distant metastasis of medullary thyroid carcinoma (MTC). Activating mutations in the RET proto-oncogene cause hereditary MTC, which provides a strong therapeutic rationale for targeting RET kinase activity. This open-label, phase II study assessed the efficacy of vandetanib, a selective oral inhibitor of RET, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, in patients with advanced hereditary MTC. METHODS Patients with unresectable locally advanced or metastatic hereditary MTC received initial treatment with once-daily oral vandetanib 300 mg. The dose was adjusted additionally in some patients on the basis of observed toxicity until disease progression or any other withdrawal criterion was met. The primary assessment was objective tumor response (by RECIST [Response Evaluation Criteria in Solid Tumors]). Results Thirty patients received initial treatment with vandetanib 300 mg/d. On the basis of investigator assessments, 20% of patients (ie, six of 30 patients) experienced a confirmed partial response (median duration of response at data cutoff, 10.2 months). An additional 53% of patients (ie, 16 of 30 patients) experienced stable disease at >/= 24 weeks, which yielded a disease control rate of 73% (ie, 22 of 30 patients). In 24 patients, serum calcitonin levels showed a 50% or greater decrease from baseline that was maintained for at least 4 weeks; 16 patients showed a similar reduction in serum carcinoembryonic antigen levels. The most common adverse events were diarrhea (70%), rash (67%), fatigue (63%), and nausea (63%). CONCLUSION In this study, vandetanib demonstrated durable objective partial responses and disease control with a manageable adverse event profile. These results demonstrate that vandetanib may provide an effective therapeutic option in patients with advanced hereditary MTC, a rare disease for which there has been no effective therapy.

Author-supplied keywords

  • Administration, Oral
  • Adult
  • Aged
  • Antigens, Tumor -- Blood
  • Antineoplastic Agents -- Administration and Dosage
  • Antineoplastic Agents -- Adverse Effects
  • Calcitonin -- Blood
  • Disease Susceptibility
  • Drug Administration Schedule
  • Enzyme Inhibitors -- Administration and Dosage
  • Enzyme Inhibitors -- Adverse Effects
  • Female
  • France
  • Heterocyclic Compounds -- Administration and Dosag
  • Heterocyclic Compounds -- Adverse Effects
  • Human
  • Kaplan-Meier Estimator
  • Male
  • Middle Age
  • Mutation
  • Neoplasms, Ductal, Lobular, and Medullary
  • Neoplasms, Ductal, Lobular, and Medullary -- Drug
  • Neoplasms, Ductal, Lobular, and Medullary -- Metab
  • Neoplasms, Ductal, Lobular, and Medullary -- Morta
  • Pedigree
  • Piperidines -- Administration and Dosage
  • Piperidines -- Adverse Effects
  • Prognosis
  • Proteins
  • Proteins -- Antagonists and Inhibitors
  • Risk Factors
  • Thyroid Neoplasms
  • Thyroid Neoplasms -- Drug Therapy
  • Thyroid Neoplasms -- Metabolism
  • Thyroid Neoplasms -- Mortality
  • Thyroid Neoplasms -- Pathology
  • Time Factors
  • Treatment Outcomes
  • Tumor Markers, Biological -- Blood
  • United States
  • Young Adult

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Wells S A Jr

  • Gosnell JE

  • Gagel RF

  • J Moley

  • D Pfister

  • Sosa JA

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free